Filing Flows

Filing Flows › Starling Oncology (STLN) › Guidance history

Starling Oncology (STLN) guidance history: what it guided and what it reported

Starling Oncology gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance 3 times and lowered it once.

Revenue

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$650M–$660M (Nov 5, 2026)—to be reported—

Gross profit

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$107M–$110M (Nov 5, 2026)—to be reported—

Free cash flow

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$5.0M–$15.0M (May 7, 2026) → lowered $5.0M–$10.0M (Nov 5, 2026)—to be reported—

Adjusted EBITDA

The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$4.0M–$6.0M (Nov 5, 2026)—to be reported—
Q4 2026$3.0M–$5.0M (Nov 5, 2026)—to be reported—
Q3 2026$500K–$1.5M (Aug 6, 2026)———

The latest quarter

Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.

Questions

Does Starling Oncology beat its guidance?

Starling Oncology gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance 3 times and lowered it once.

How often does Starling Oncology raise guidance?

Its earnings releases raised guidance 3 times and lowered it once since May 7, 2026.

Latest guidance and outlook →

Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.